Jefferies recently laid out a roadmap for biotech in 2026, pointing to a mix of late-stage regulatory catalysts, underappreciated plays ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE